Advice
following an abbreviated submission:
eslicarbazepine acetate (Zebinix®) is accepted for restricted use within NHSScotland.
Indication under review: as adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation.
SMC restriction: patients with highly refractory epilepsy who have been heavily pre-treated and remain uncontrolled with existing anti-epileptic drugs.
SMC has previously accepted eslicarbazepine acetate for restricted use as adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation.
Download detailed advice46KB (PDF)
Medicine details
- Medicine name:
- eslicarbazepine acetate (Zebinix)
- SMC ID:
- SMC2087
- Indication:
- For adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation.
- Pharmaceutical company
- Eisai Ltd
- BNF chapter
- Central nervous system
- Submission type
- Abbreviated
- Status
- Restricted
- Date advice published
- 11 February 2019